Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Stroke 1Stomach Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Kidney Failure, Chronic 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Artery Disease 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1COVID-19 1Breast Neoplasms 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Massage 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pulmonary Disease, Chronic Obstructive × tocilizumab × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡